NASDAQ:RLAY - Nasdaq - US75943R1023 - Common Stock - Currency: USD
We assign a fundamental rating of 4 out of 10 to RLAY. RLAY was compared to 567 industry peers in the Biotechnology industry. While RLAY has a great health rating, there are worries on its profitability. While showing a medium growth rate, RLAY is valued expensive at the moment.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -38.76% | ||
ROE | -43.42% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | 0.45 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 15.95 | ||
Quick Ratio | 15.95 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
3.25
-0.04 (-1.22%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 55.37 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 0.71 | ||
P/tB | 0.71 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -38.76% | ||
ROE | -43.42% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 36.93% | ||
Cap/Sales | 20.17% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 15.95 | ||
Quick Ratio | 15.95 | ||
Altman-Z | 0.45 |